Related references
Note: Only part of the references are listed.On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy
Pablo Nenclares et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with clinical outcome in recurrent or metastatic head and neck cancer patients treated with nivolumab
Tsutomu Ueda et al.
ACTA OTO-LARYNGOLOGICA (2020)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer
Yueming Zhang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Izabela Lasniska et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
1162PA nomogram based prognostic score to predict overall survival (OS) in recurrent-metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
L Mousa et al.
ANNALS OF ONCOLOGY (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Immunotherapy in head and neck cancer: The great challenge of patient selection
Martina Napolitano et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: A meta-analysis
Yukinori Takenaka et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2018)
An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy
Ying Wang et al.
BMC CANCER (2018)
Comprehensive Analysis of the Neutrophil-to-Lymphocyte Ratio for Preoperative Prognostic Prediction Nomogram in Gastric Cancer
Jong-Ho Choi et al.
WORLD JOURNAL OF SURGERY (2018)
Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
Tanguy Y. Seiwert et al.
CANCER RESEARCH (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review
Mallika Lala et al.
ORAL ONCOLOGY (2018)
1087PAssociation of LIPI score with immune checkpoint inhibitors (ICI) outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (pts)
R G Herrera Gomez et al.
ANNALS OF ONCOLOGY (2018)
Non-invasive assessment of tumor PD-L1 status with circulating tumor cells
Bryan C. Ulrich et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
Frameshift events predict anti-PD-1/L1 response in head and neck cancer
Glenn J. Hanna et al.
JCI INSIGHT (2018)
Methods of measurement for tumor mutational burden in tumor tissue
Barbara Melendez et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
Zhongwu Lai et al.
NUCLEIC ACIDS RESEARCH (2016)
Mutational signatures associated with tobacco smoking in human cancer
Ludmil B. Alexandrov et al.
SCIENCE (2016)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Share Paper
